Morgan Stanley Maintains Overweight on Radius Health, Lowers Price Target to $36

Morgan Stanley maintains Radius Health (NASDAQ:RDUS) with a Overweight and lowers the price target from $42 to $36.

Benzinga · 11/13/2019 13:14

Morgan Stanley maintains Radius Health (NASDAQ:RDUS) with a Overweight and lowers the price target from $42 to $36.